Uludag Universitesi

Bursa 16059

3 studies enrolling now · 8 studies all time

What they study most

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Crohn's Disease, Neoplasm Metastasis, Obesity, Obesity or Overweight, Type 2 Diabetes, Ulcerative Colitis

Studies at this site

• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity — Running, not enrolling
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed